Establishing Correlation Between Aerosol and Surface Microbial Populations

February 2, 2018
F. Andreas Toba

F. Andreas Toba is Vice President, Intact Pharma Operations, MedInstill Development.

,
David A. Miller

David A. Miller is Manager, Device Performance Engineering, MedInstill Development.

,
Bryan R. Campbell

Bryan R. Campbell is a Doctor of Osteopathic Medicine at Touro University Nevada.

,
Debashis Sahoo

Debashis Sahoo is Executive Vice-President, Regulators & Key Customers, MedInstill Development.

,
Daniel Py

Daniel Py is chairman and CEO, MedInstill Development.

,
James P. Agalloco

James P. Agalloco is the president of Agalloco & Associates, P.O. Box 899, Belle Mead, NJ 08502, tel. 908.874.7558, jagalloco@aol.com. He is also a member of Pharmaceutical Technology’s editorial advisory board.

Pharmaceutical Technology, Pharmaceutical Technology-02-02-2018, Volume 42, Issue 2
Page Number: 44–51

The following study describes a methodology to establish, control, and characterize an aerosolized bioburden within a test chamber and determine the settling rate of the bioburden.

Pharmaceutical and nutritional package integrity is often studied by incidental contamination, via immersion or aerosol microbiological challenge tests. Aerosol tests rely upon microorganisms settling from the atmosphere onto critical surfaces. Maintenance of a contaminated atmosphere is necessary to create the conditions that will cause a constant settling rate of the test microorganisms. Both parameters--maintenance of bioburden and duration of exposure--have to be monitored and controlled. It is important to understand the limitations of aerosol tests where the microbial contamination conditions are not maintained over the duration of the test. The following study describes a methodology to establish, control, and characterize an aerosolized bioburden within a test chamber and determine the settling rate of the bioburden. The intention of this paper is to stimulate the necessary discussion for the establishment of the standard criteria for all aerosol tests to generate comparable and reproducible data.

Peer-Reviewed

Submitted: Aug. 25, 2017
Accepted: Dec. 8, 2017

About the Authors

F. Andreas Toba* is vice president, Intact Pharma Operations, atoba@medinstill.com; David A. Miller is manager, Device Performance Engineering; Debashis Sahoo is executive vice-president, Regulators & Key Customers; and Daniel Py is chairman and CEO-all at MedInstill Development. Bryan R. Campbell is a Doctor of Osteopathic Medicine at Touro University Nevada; and James P. Agalloco is president, Agalloco & Associates, and a member of the Pharmaceutical Technology editorial advisory board.

*To whom all correspondence should be addressed.

Article Details

Pharmaceutical Technology
Vol. 42, No. 2
February 2018
Page: 44–51

Citation

When referring to this article, please cite as F.A. Toba et. al, “Establishing Correlation Between Aerosol and Surface Microbial Populations,” Pharmaceutical Technology 42 (2) 2018. 

download issueDownload Issue : Pharmaceutical Technology-02-02-2018